Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists

被引:17
|
作者
Jitsuoka, Makoto [1 ]
Tsukahara, Daisuke [1 ]
Ito, Sayaka [1 ]
Tanaka, Takeshi [1 ]
Takenaga, Norihiro [1 ]
Tokita, Shigeru [1 ]
Sato, Nagaaki [1 ]
机构
[1] Banyu Pharmaceut Co Ltd, Merck Res Labs, Tsukuba Res Inst, Tsukuba, Ibaraki 3002611, Japan
关键词
histamine H-3 inverse agonist; spiro-isobenzofuranone; PET tracer; brain permeability;
D O I
10.1016/j.bmcl.2008.07.125
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Spiro-isobenzofuranones 1a and 1b were discovered as potent, selective, and brain-penetrable non-imidazole H-3 receptor inverse agonists. Our corporate sample collection was screened to identify 2a as a lead. Recognizing the right-hand portion of 2a as an essential pharmacophore, an extensive screen of the left-hand piperidine portion was carried out to yield the potent spiro-derivatives 2t-x. Spiro-isobenzofuranone 2x, the most potent among the derivatives, was converted to the corresponding amide 1a, which possessed dramatically improved H3 activity (IC50 = 0.72 nM; more than 20-fold improvement over 2x). Further elaboration led to the identification of 1b, a 5-methoxy derivative with an IC50 of 0.54 nM. Our studies demonstrated that derivatives 1a and 1b to be potent, selective, and brain-penetrable H-3 inverse agonists. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5101 / 5106
页数:6
相关论文
共 50 条
  • [21] Discovery of a New Class of Non-imidazole Oxazoline-Based Histamine H3 Receptor (H3R) Inverse Agonists
    Celanire, Sylvain
    Wijtmans, Maikel
    Christophe, Bernard
    Collart, Philippe
    de Esch, Iwan
    Dassesse, Donald
    Delaunoy, Christel
    Denonne, Frederic
    Durieu, Veronique
    Gelens, Edith
    Gillard, Michel
    Lallemand, Benedicte
    Lamberty, Yves
    Lebon, Florence
    Nicolas, Jean-Marie
    Quere, Luc
    Snip, Erwin
    Vanbellinghen, Alain
    Van Houtvin, Nathalie
    Verbois, Valerie
    Timmerman, Henk
    Talaga, Patrice
    Leurs, Rob
    Provins, Laurent
    CHEMMEDCHEM, 2009, 4 (07) : 1063 - 1068
  • [22] Novel morpholine ketone analogs as potent histamine H3 receptor inverse agonists with wake activity
    Sundar, Babu G.
    Bailey, Thomas R.
    Dunn, Derek
    Hostetler, Greg A.
    Chatterjee, Sankar
    Bacon, Edward R.
    Yue, Christoph
    Schweizer, Dominique
    Aimone, Lisa D.
    Gruner, John A.
    Lyons, Jacquelyn
    Raddatz, Rita
    Lesur, Brigitte
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (04) : 1546 - 1549
  • [23] Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists
    Josef, Kurt A.
    Aimone, Lisa D.
    Lyons, Jacquelyn
    Raddatz, Rita
    Hudkins, Robert L.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (12) : 4198 - 4202
  • [24] Partial agonists for the histamine H3 receptor with high in vivo activity
    Schunack, W
    Sasse, A
    Stark, H
    Elz, S
    Ligneau, X
    Ganellin, CR
    Schwartz, JC
    HISTAMINE RESEARCH IN THE NEW MILLENNIUM, 2001, 1224 : 77 - 82
  • [25] Synthesis and structure-activity relationships of conformationally constrained histamine H3 receptor agonists
    Kitbunnadaj, R
    Zuiderveld, OP
    De Esch, IJP
    Vollinga, RC
    Bakker, R
    Lutz, M
    Spek, AL
    Cavoy, E
    Deltent, MF
    Menge, WMPB
    Timmerman, H
    Leurs, R
    JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (25) : 5445 - 5457
  • [26] Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017)
    Lazewska, Dorota
    Kiec-Kononowicz, Katarzyna
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2018, 28 (03) : 175 - 196
  • [27] HISTAMINE H3 RECEPTOR INVERSE AGONISTS: WAKE PROMOTION WITHOUT DRUG ABUSE RISK SHOWN WITH PITOLISANT
    Ligneau, X.
    Uguen, M.
    Perrin, D.
    Belliard, S.
    Beardsley, P. M.
    Robert, P.
    Scart-Gres, C.
    Joulin, Y.
    Lecomte, J. M.
    Schwartz, J. C.
    INFLAMMATION RESEARCH, 2018, 67 : S24 - S24
  • [28] The discovery of the benzazepine class of histamine H3 receptor antagonists
    Wilson, David M.
    Apps, James
    Bailey, Nicholas
    Bamford, Mark J.
    Beresford, Isabel J.
    Briggs, Michael A.
    Calver, Andrew R.
    Crook, Barry
    Davis, Robert P.
    Davis, Susannah
    Dean, David K.
    Harris, Leanne
    Heightman, Tom D.
    Panchal, Terry
    Parr, Christopher A.
    Quashie, Nigel
    Steadman, Jon G. A.
    Schogger, Joanne
    Sehmi, Sanjeet S.
    Stean, Tania O.
    Takle, Andrew K.
    Trail, Brenda K.
    White, Trevor
    Witherington, Jason
    Worby, Angela
    Medhurst, Andrew D.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (24) : 6897 - 6901
  • [29] A scalable synthesis of a histamine H3 receptor antagonist
    Mani, NS
    Jablonowski, JA
    Jones, TK
    JOURNAL OF ORGANIC CHEMISTRY, 2004, 69 (23): : 8115 - 8117
  • [30] Differences in pharmacological properties of histamine H3 receptor agonists and antagonists revealed at two human H3 receptor isoforms
    T. A. Esbenshade
    K. M. Krueger
    B. B. Yao
    D. G. Witte
    B. R. Estvander
    J. L. Baranowski
    T. R. Miller
    A. A. Hancock
    Inflammation Research, 2006, 55 : S45 - S46